Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects
| Autor: | M. B. Fennerty, Andrew M. Snoddy, David A. Peura, D. S. Riff |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Lansoprazole Proton-pump inhibitor Placebo Gastroenterology 2-Pyridinylmethylsulfinylbenzimidazoles Drug Administration Schedule Young Adult Double-Blind Method Heartburn Internal medicine otorhinolaryngologic diseases medicine Humans Pharmacology (medical) Young adult Aged Morning Aged 80 and over Dose-Response Relationship Drug Hepatology business.industry digestive oral and skin physiology Reflux Middle Aged Anti-Ulcer Agents humanities digestive system diseases Surgery Clinical trial Female medicine.symptom business medicine.drug |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 30:459-468 |
| ISSN: | 1365-2036 0269-2813 |
| DOI: | 10.1111/j.1365-2036.2009.04064.x |
| Popis: | Summary Background Frequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms. Aim To evaluate the efficacy and safety of lansoprazole in self-treating subjects with frequent nocturnal heartburn. Methods A total of 864 subjects with heartburn on ≥2 days/week over the past month were randomized to double-blind treatment with lansoprazole 15 or 30 mg or placebo each morning. Endpoints were percentage of nighttimes without heartburn (primary), percentage of 24-h days without heartburn and percentage of subjects without heartburn on day 1. Results Mean percentage of nighttimes without heartburn was significantly greater with lansoprazole 15 mg (61.3%) or lansoprazole 30 mg (61.7%) vs. placebo (47.8%) over 14 days (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |